SAN DIEGO--Privately held Structural Bioinformatics here announced that BioChem Pharma, a Canadian biopharmaceutical company, has accepted a lead compound for the treatment of a human viral infectious disease, triggering a milestone payment in the company's collaboration with BioChem Pharma.
Structural Bioinformatics began collaborating with BioChem in August 1997 to find leads for certain viral and cancer targets.
The new lead compound will now be further developed by BioChem. Structural Bioinformatics will receive future fees upon the fulfillment of additional milestones, including the successful completion of clinical trials.